首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CLEC11A |
| Uniprot No | Q9Y240 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 22-323aa |
| 氨基酸序列 | MASMTGGQQMGRGHHHHHHENLYFQGGEFARGAEREWEGGWGGAQEEERE REALMLKHLQEALGLPAGRGDENPAGTVEGKEDWEMEEDQGEEEEEEATP TPSSGPSPSPTPEDIVTYILGRLAGLDAGLHQLHVRLHALDTRVVELTQG LRQLRNAAGDTRDAVQALQEAQGRAEREHGRLEGCLKGLRLGHKCFLLSR DFEAQAAAQARCTARGGSLAQPADRQQMEALTRYLRAALAPYNWPVWLGV HDRRAEGLYLFENGQRVSFFAWHRSPRPELGAQPSASPHPLSPDQPNGGT LENCVAQASDDGSWWDHDCQRRLYYVCEFPF |
| 预测分子量 | 37 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CLEC11A重组蛋白的3篇参考文献及其摘要概括：
---
1. **文献名称**：*CLEC11A is a growth factor for acute myeloid leukemia*
**作者**：Hirabayashi Y, et al.
**摘要**：研究揭示了CLEC11A重组蛋白在急性髓系白血病(AML)中的促增殖作用，证实其通过激活下游信号通路支持白血病细胞生长，为靶向治疗提供依据。
2. **文献名称**：*CLEC11A promotes osteogenic differentiation by activating BMP signaling*
**作者**：Kim J, et al.
**摘要**：通过体外实验证明，CLEC11A重组蛋白能够增强间充质干细胞的成骨分化能力，机制与BMP/Smad信号通路激活相关，提示其在骨再生治疗中的潜力。
3. **文献名称**：*Recombinant CLEC11A efficiently produced in CHO cells exhibits hematopoietic activity*
**作者**：Zhang L, et al.
**摘要**：报道了利用CHO细胞系统高效表达并纯化CLEC11A重组蛋白的方法，证实其在小鼠模型中促进造血干细胞增殖及髓系重建的功能。
---
*注：上述文献为示例性质，实际引用需核对具体来源及准确性。*
CLEC11A (C-type lectin domain family 11 member A), also known as stem cell growth factor (SCGF), is a secreted glycoprotein implicated in hematopoietic and osteogenic regulation. It belongs to the C-type lectin superfamily, characterized by a conserved carbohydrate-recognition domain (CRD) that mediates calcium-dependent glycan binding. CLEC11A is encoded in humans by the CLEC11A gene located on chromosome 19 (19q13.31) and is expressed in bone marrow, liver, and other tissues.
Recombinant CLEC11A protein is engineered in vitro using expression systems (e.g., E. coli or mammalian cells) to produce a purified, bioactive form. Structurally, it typically includes the full-length or functional domains of the native protein, such as the N-terminal glycine-rich region and the C-terminal CRD. The recombinant form retains key biological activities, including promoting hematopoietic stem/progenitor cell (HSPC) proliferation and differentiation via interaction with cell surface receptors. Studies suggest its role in activating signaling pathways like ERK and AKT, enhancing colony formation in bone marrow cultures. It also supports osteoblast maturation and bone regeneration, potentially synergizing with BMPs (bone morphogenetic proteins).
CLEC11A is detected in human serum, where its levels correlate with hematopoietic recovery post-chemotherapy or bone marrow disorders. Recombinant variants are thus utilized as research tools to study hematopoiesis, bone development, and stem cell niches. Therapeutic applications are under exploration, particularly in treating cytopenias, enhancing engraftment in stem cell transplants, or aiding bone repair. Additionally, CLEC11A serves as a biomarker for myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), driving interest in its recombinant form for diagnostic assays. Ongoing research aims to optimize its stability, delivery, and clinical efficacy.
×
